nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.05.2012 | Review

The bodies fight against cancer: is human leucocyte antigen (HLA) class 1 the key?

verfasst von: Arfon G. M. T. Powell, Paul G. Horgan, Joanne Edwards

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Loss of human leucocyte antigen (HLA) class I expression has been implicated in tumour progression and metastasis; however, studies reporting its relationship with long-term survival are few in number with conflicting reports. The aim of this review was to assess the prognostic value of HLA class I expression in gastrointestinal cancer.

Methods

Major electronic databases, including Medline, Embase, Cochrane Library and Pubmed were searched for original studies. Two independent reviewers assessed each study against inclusion and exclusion criteria. All data were specific to gastrointestinal cancer surgery.

Results

Fourteen original studies were included in this present review. In oesophageal cancer, reduced expression of HLA-A, HLA-B, HLA-C and HLA-G were associated with poorer survival. However, in gastric and colorectal cancer, the prognostic value of HLA-A, HLA-B, HLA-C and HLA-G remains conflicting. Antibody use and reporting methodology was different between all 14 studies examined.

Conclusion

Variability in antibody use makes it difficult to validate HLA class I expression as an independent prognostic marker in GI cancer. Consensus guidelines, incorporating heavy and light chain antibodies, are required with further studies on HLA class I expression being performed to validate its prognostic value.

Bar-Eli M, Battifora H, Cline MJ (1988) Alterations of class I HLA genes in human colon cancers. Hum Genet 78:86–89CrossRefPubMed

Benevolo M, Mottolese M, Piperno G, Sperduti I, Cione A, Sibilio L, Martayan A, Donnorso RP, Cosimelli M, Giacomini P (2007) HLA-A, -B, -C expression in colon carcinoma mimics that of the normal colonic mucosa and is prognostically relevant. Am J Surg Pathol 31:76–84CrossRefPubMed

Brodsky RM, Parham P, Barnstable C, Crumpton M, Bodmet W (1979) Monoclonal antibodies for analysis of the HLA system. Immunol Rev 47:3–61CrossRefPubMed

Cancerstats (2010) http://www.cancerresearchuk.org. Accessed 14 Feb 2012

Chatzipetrou MA, Tarassi KE, Konstadoulakis MM, Pappas HE, Zafirellis KD, Athanassiades TE, Papadopoulos SA, Panousopoulos DG, Golematis BC, Papasteriades CA (1999) Human leukocyte antigens as genetic markers in colorectal carcinoma. Dis Colon Rectum 42:66–70CrossRefPubMed

Crumley AB, Going JJ, Hilmy M, Dutta S, Tannahill C, McKernan M, Edwards J, Stuart RC, McMillan DC (2011) Interrelationships between tumor proliferative activity, leucocyte and macrophage infiltration, systemic inflammatory response, and survival in patients selected for potentially curative resection for gastroesophageal cancer. Ann Surg Oncol 18:2604–2612CrossRefPubMed

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964CrossRefPubMed

Goepel JR, Rees RC, Rogers K, Stoddard CJ, Thomas WE, Shepherd L (1991) Loss of monomorphic and polymorphic HLA antigens in metastatic breast and colon carcinoma. Br J Cancer 64:880–883CrossRefPubMed

Hosch SB, Meyer AF, Schneider C, Stoecklein N, Prenzel KL, Pantel K, Broelsch CE, Izbicki JR (1997a) Expression and prognostic significance of HLA class I, ICAN-1, and tumor-infiltrating lymphocytes in esophageal cancer. J Gastrointest Surg 1:316–323CrossRefPubMed

Hosch SB, Izbicki JR, Pichlmeier U, Stoecklein N, Niendorf A, Knoefel WT, Broelsch CE, Pantel K (1997b) Expression and prognostic significance of immunoregulatory molecules in esophageal cancer. Int J Cancer 74:582–587CrossRefPubMed

Ishigami S, Natsugoe S, Nakajo A, Arigami T, Kitazono M, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Sasaki K, Aikou T (2008) HLA-class 1 expression in gastric cancer. J Surg Oncol 97:605–608CrossRefPubMed

Kaklamanis L, Gatter KC, Hill AB, Mortensen N, Harris AL, Krausa P, McMichael A, Bodmer JG, Bodmer WF (1992) Loss of HLA class-I alleles, heavy chains and beta 2-microglobulin in colorectal cancer. Int J Cancer 51:379–385CrossRefPubMed

Kasajima A, Sers C, Sasano H, Jöhrens K, Stenzinger A, Noske A, Buckendahl AC, Darb-Esfahani S, Müller BM, Budczies J, Lehman A, Dietel M, Denkert C, Weichert W (2010) Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer. Hum Pathol 41:1758–1769CrossRefPubMed

Klintrup K, Makinen JM, Kauppila S, Vare PO, Melkko J, Tuominen H, Tuppurainen K, Makela J, Karttunen TJ, Makinen MJ (2005) Inflammation and prognosis in colorectal cancer. Eur J Cancer 41:2645–2654CrossRefPubMed

Kloor M, Becker C, Benner A, Woerner SM, Gebert J, Ferrone S, von KnebelDoeberitz M (2005) Immunoselective pressure and human leukocyte antigen class 1 antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res 65:6418–6424CrossRefPubMed

McArdle CS, Hole DJ (2002) Outcome following surgery for colorectal cancer: analysis by hospital after adjustment for case-mix and deprivation. Br J Cancer 86:331–335CrossRefPubMed

McMillan DC (2009) Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 12:223–226CrossRefPubMed

Menon AG, Morreau H, Tollenaar RA, Alphenaar E, Van Puijenbroek M, Putter H, Janssen-Van Rhijn CM, Van De Velde CJ, Fleuren GJ, Kuppen PJ (2002) Down-regulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients. Lab Invest 82:1725–1733PubMed

Mizukami Y, Kono K, Maruyama T, Watanabe M, Kawaguchi Y, Kamimura K, Fujii H (2008) Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma. Br J Cancer 99:1462–1467CrossRefPubMed

Möller P, Koretz K, Schlag P, Momburg F (1991a) Frequency of abnormal expression of HLA-A, B, C and HLA-DR molecules, invariant chain, and LFA-3 (CD58) in colorectal carcinoma and its impact on tumour recurrence. Int J Cancer Suppl 6:155–162CrossRefPubMed

Möller P, Momburg F, Koretz K, Moldenhauer G, Herfarth C, Otto HF, Hämmerling GJ, Schlag P (1991b) Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma. Cancer Res 51:729–736PubMed

Momburg F, Ziegler A, Harpprecht J, Möller P, Moldenhauer G, Hämmerling GJ (1989) Selective loss of HLA-A or HLA-B antigen expression in colon carcinoma. J Immunol 142:352–358PubMed

Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F (2003) Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 171:1918–1926PubMed

Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM (1997) Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 182:318–324CrossRefPubMed

Roxburgh CSD, Salmond JM, Horgan PG, Oien KA, McMillan DC (2009) Tumour inflammatory infiltrate predicts survival following curative resection for node negative colorectal cancer. Eur J Surg 45:2138–2145

Seitz C, Uchanska-Ziegler B, Zank A, Ziegler A (1998) The monoclonal antibody HCA2 recognises a broadly shared epitope on selected classical as well as several non-classical HLA class I molecules. MolImmunol 35:819–827

Sernee MF, Ploegh HL, Schust DJ (1998) Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents. Mol Immunol 35:177–188CrossRefPubMed

Shen YQ, Zhang JQ, Miao FQ, Zhang JM, Jiang Q, Chen H, Shan XN, Xie W (2005) Relationship between the downregulation of HLA class I antigen and clinicopathological significance in gastric cancer. World J Gastroenterol 11:3628–3631PubMed

Simpson JA, Al-Attar A, Watson NF, Scholefield JH, Ilyas M, Durrant LG (2010) Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer. Gut 59:926–933CrossRefPubMed

Speetjens FM, de Bruin EC, Morreau H, Zeestraten EC, Putter H, van Krieken JH, van Buren MM, van Velzen M, Dekker-Ensink NG, van de Velde CJ, Kuppen PJ (2008) Clinical impact of HLA class I expression in rectal cancer. Cancer Immunol Immunother 57:601–609CrossRefPubMed

Stam NJ, Spits H, Ploegh HL (1986) Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 137:2299–2306PubMed

Stam NJ, Vroom TM, Peters PJ, Pastoors EB, Ploegh HL (1990) HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol 2:113–125CrossRefPubMed

Stein B, Momburg F, Schwarz V, Schlag P, Moldenhauer G, Möller P (1988) Reduction or loss of HLA-A, B, C antigens in colorectal carcinoma appears not to influence survival. Br J Cancer 57:364–368CrossRefPubMed

Ueda Y, Ishikawa K, Shiraishi N, Yokoyama S, Kitano S (2008) Clinical significance of HLA class I heavy chain expression in patients with gastric cancer. J Surg Oncol 97:451–455CrossRefPubMed

Vakilla J, Lotze MT (2004) Inflammation and necrosis promote tumour growth. Nat Cancer Rev 4:641–648

Van den Ingh HF, Ruiter DJ, Griffioen G, van Muijen GN, Ferrone S (1987) HLA antigens in colorectal tumours—low expression of HLA class I antigens in mucinous colorectal carcinomas. Br J Cancer 55:125–130CrossRefPubMed

Watson NFS, Ramage JM, Madjd Z, Spendlove I, Ellis IO, Schofield JH, Durrant LG (2006) Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class 1 expression correlates with poor prognosis. Int J Cancer 118:6–10CrossRefPubMed

Ye SR, Yang H, Li K, Dong DD, Lin XM, Yie SM (2007) Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol 20:375–383CrossRefPubMed

Yie SM, Yang H, Ye SR, Li K, Dong DD, Lin XM (2007a) Expression of human leukocyte antigen G (HLA-G) correlates with poor prognosis in gastric cancer. Ann Surg Oncol 14:2721–2729CrossRefPubMed

Yie SM, Yang H, Ye SR, Li K, Dong DD, Lin XM (2007b) Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma. Am J Clin Pathol 128:1002–1009CrossRefPubMed

Titel: The bodies fight against cancer: is human leucocyte antigen (HLA) class 1 the key?
verfasst von: Arfon G. M. T. Powell
Paul G. Horgan
Joanne Edwards
Publikationsdatum: 01.05.2012
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 5/2012
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-012-1192-4

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The bodies fight against cancer: is human leucocyte antigen (HLA) class 1 the key?

Abstract

Introduction

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2012

Application of ex vivo 1H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases

Serum prolidase activity, oxidative stress, and nitric oxide levels in patients with bladder cancer

Effects of the inhibition of cytosolic phospholipase A2α in non-small cell lung cancer cells

Delayed formation of FancD2 foci in glioma stem cells treated with ionizing radiation

Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment

The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: a meta-analysis and systemic review

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie